Top

Published in:

Open Access 01-12-2011 | Commentary

Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration

Author: Janin Schulte

Published in: BMC Medicine | Issue 1/2011

Abstract

Currently, there is much interest in identifying clinically relevant biomarkers, as they have the potential to be high utility non-invasive tools for early diagnosis and reliable patient monitoring in numerous conditions. Since its discovery almost 15 years ago, research on the ubiquitous antioxidant enzyme peroxiredoxin 4 (Prx4) has culminated in the recognition that Prx4 levels are different in blood drawn from the healthy general population and patients with acute or chronic diseases. In this commentary, the most striking research data from different in vitro approaches, animal models and human observational studies are discussed collectively, highlighting the clinical importance of Prx4 as a multifunctional staging and prognosis biomarker. In this context, the oxidative state of patients may be reflected by intra- and extracellular Prx4 levels, redox state, oligomerization and nitro-oxidative modifications of the enzyme. A consolidated model of the potential role and origin of circulating Prx4 is presented to stimulate further investigations in light of the current biomarker situation.

Available only for authorised users

Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 2006, 52 (4): 601-623. 10.1373/clinchem.2005.061408.CrossRefPubMed

Haridas V, Ni J, Meager A, Su J, Yu GL, Zhai Y, Kyaw H, Akama KT, Hu J, Van Eldik L, Aggarwal BB: TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase. J Immunol. 1998, 161 (1): 1-6.PubMed

Tavender TJ, Bulleid NJ: Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation. J Cell Sci. 2010, 123 (Pt 15): 2672-2679.CrossRefPubMedPubMedCentral

Jin D-Y, Chae HZ, Rhee SG, Jeang K-T: Regulatory role for a novel human thioredoxin peroxidase in NF-kB activation. J Biol Chem. 1997, 272 (49): 30952-30961. 10.1074/jbc.272.49.30952.CrossRefPubMed

Wood ZA, Schröder E, Harris JR, Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003, 28 (1): 32-40. 10.1016/S0968-0004(02)00003-8.CrossRefPubMed

Yu S, Mu Y, Ao J, Chen X: Peroxiredoxin IV regulates pro-inflammatory responses in large yellow croaker (Pseudosciaena crocea) and protects against bacterial challenge. J Proteome Res. 2010, 9 (3): 1424-1436. 10.1021/pr900961x.CrossRefPubMed

Rhee SG, Woo HA: Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones. Antioxid Redox Signal. 2011, 15 (3): 781-794. 10.1089/ars.2010.3393.CrossRefPubMed

O'Neill JS, Reddy AB: Circadian clocks in human red blood cells. Nature. 2011, 469 (7331): 498-503. 10.1038/nature09702.CrossRefPubMedPubMedCentral

Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N: Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem. 2000, 127 (3): 493-501.CrossRefPubMed

10.

Chang X, Cui Y, Zong M, Zhao Y, Yan X, Chen Y, Han J: Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol. 2009, 36 (5): 872-880. 10.3899/jrheum.080939.CrossRefPubMed

11.

Schulte J, Struck J, Bergmann A, Köhrle J: Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum. Clin Chim Acta. 2010, 411 (17-18): 1258-1263. 10.1016/j.cca.2010.05.016.CrossRefPubMed

12.

Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, Schulte J, Köhrle J, Hartmann O, Giersdorf S, Bingisser R: Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med. 2011, 18 (8): 851-859. 10.1111/j.1553-2712.2011.01126.x.CrossRefPubMed

13.

Schulte J, Struck J, Köhrle J, Müller B: Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock. 2011, 35 (5): 460-465. 10.1097/SHK.0b013e3182115f40.CrossRefPubMed

14.

Soini Y, Haapasaari KM, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P: 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. Int J Clin Exp Pathol. 2011, 4 (3): 267-275.PubMedPubMedCentral

15.

Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG: Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002, 8 (7): 2298-2305.PubMed

16.

Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U: DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer. 2009, 19 (6): 1047-1051. 10.1111/IGC.0b013e3181ad0f0d.CrossRefPubMed

17.

Karihtala P, Kauppila S, Soini Y, Jukkola-Vuorinen A: Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011, 11: 262-10.1186/1471-2407-11-262.CrossRefPubMedPubMedCentral

18.

Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003, 9 (9): 3418-3424.PubMed

19.

Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS, Chi LM: Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res. 2011, 10 (11): 4935-4947. 10.1021/pr200311p.CrossRefPubMed

20.

Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 2011, 71 (7): 755-765. 10.1002/pros.21292.CrossRefPubMed

21.

Dreja T, Jovanovic Z, Rasche A, Kluge R, Herwig R, Tung YC, Joost HG, Yeo GS, Al-Hasani H: Diet-induced gene expression of isolated pancreatic islets from a polygenic mouse model of the metabolic syndrome. Diabetologia. 2010, 53 (2): 309-320. 10.1007/s00125-009-1576-4.CrossRefPubMed

22.

Jiang YL, Ning Y, Ma XL, Liu YY, Wang Y, Zhang Z, Shan CX, Xu YD, Yin LM, Yang YQ: Alteration of the proteome profile of the pancreas in diabetic rats induced by streptozotocin. Int J Mol Med. 2011, 28 (2): 153-160.PubMed

23.

Xie X, Li S, Liu S, Lu Y, Shen P, Ji J: Proteomic analysis of mouse islets after multiple low-dose streptozotocin injection. Biochim Biophys Acta. 2008, 1784 (2): 276-284.CrossRefPubMed

24.

Wang X, Zhang S, Sun C, Yuan ZG, Wu X, Wang D, Ding Z, Hu R: Proteomic profiles of mouse neuro n2a cells infected with variant virulence of rabies viruses. J Microbiol Biotechnol. 2011, 21 (4): 366-373.PubMed

25.

Jamaluddin M, Wiktorowicz JE, Soman KV, Boldogh I, Forbus JD, Spratt H, Garofalo RP, Brasier AR: Role of peroxiredoxin 1 and peroxiredoxin 4 in protection of respiratory syncytial virus-induced cysteinyl oxidation of nuclear cytoskeletal proteins. J Virol. 2010, 84 (18): 9533-9545. 10.1128/JVI.01005-10.CrossRefPubMedPubMedCentral

26.

Knight M, Raghavan N, Goodall C, Cousin C, Ittiprasert W, Sayed A, Miller A, Williams DL, Bayne CJ: Biomphalaria glabrata peroxiredoxin: effect of Schistosoma mansoni infection on differential gene regulation. Mol Biochem Parasitol. 2009, 167 (1): 20-31. 10.1016/j.molbiopara.2009.04.002.CrossRefPubMedPubMedCentral

27.

Mota S, Mendes M, Freitas N, Penque D, Coelho AV, Cunha C: Proteome analysis of a human liver carcinoma cell line stably expressing hepatitis delta virus ribonucleoproteins. J Proteomics. 2009, 72 (4): 616-627. 10.1016/j.jprot.2008.12.003.CrossRefPubMed

28.

Young R, Hayes JD, Brown K, Wolf CR, Whitelaw CB: Peroxiredoxin gene expression signatures in liver reflect toxic insult. Assay Drug Dev Technol. 2010, 8 (4): 512-517. 10.1089/adt.2009.0246.CrossRefPubMed

29.

Anderson R, Schmidt R: Clinical biomarkers in sepsis. Front Biosci (Elite Ed). 2010, 2: 504-520.

30.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med. 2010, 49 (11): 1603-1616. 10.1016/j.freeradbiomed.2010.09.006.CrossRefPubMedPubMedCentral

31.

Uno K, Nicholls SJ: Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med. 2010, 4 (3): 361-373. 10.2217/bmm.10.57.CrossRefPubMed

32.

Liu G, Botting CH, Evans KM, Walton JAG, Xu G, Slawin AMZ, Westwood NJ: Optimisation of conoidin A, a peroxiredoxin inhibitor. Chem Med Chem. 2010, 5: 41-45.CrossRefPubMed

33.

Mitsumoto A, Takanezawa Y, Okawa K, Iwamatsu A, Nakagawa Y: Variants of peroxiredoxins expression in response to hydroperoxide stress. Free Radic Biol Med. 2001, 30 (6): 625-635. 10.1016/S0891-5849(00)00503-7.CrossRefPubMed

34.

Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004, 111 (4): 514-521. 10.1002/ijc.20294.CrossRefPubMed

35.

Huo R, He Y, Zhao C, Guo X-J, Lin M, Sha J-H: Identification of human spermatogenesis-related proteins by comparative proteomic analysis: a preliminary study. Fertil Steril. 2008, 90 (4): 1109-1118. 10.1016/j.fertnstert.2007.07.1342.CrossRefPubMed

36.

Matsuki S, Sasagawa I, Iuchi Y, Fujii J: Impaired expression of peroxiredoxin 4 in damaged testes by artificial cryptorchidism. Redox Rep. 2002, 7 (5): 276-278. 10.1179/135100002125000785.CrossRefPubMed

37.

Ikeda Y, Ito R, Ihara H, Okada T, Fujii J: Expression of N-terminally truncated forms of rat peroxiredoxin-4 in insect cells. Protein Expr Purif. 2010, 72 (1): 1-7. 10.1016/j.pep.2010.02.001.CrossRefPubMed

38.

O'Flaherty C, Rico de Souza A: Hydrogen peroxide modifies human sperm peroxiredoxins in a dose-dependent manner. Biol Reprod. 2011, 84 (2): 238-247. 10.1095/biolreprod.110.085712.CrossRefPubMed

39.

Yim SH, Kim YJ, Oh SY, Fujii J, Zhang Y, Gladyshev VN, Rhee SG: Identification and characterization of an alternatively transcribed form of peroxiredoxin IV that is specifically expressed in spermatids of the postpubertal mouse testis. J Biol Chem. 2011, 286 (45): 39002-39012. 10.1074/jbc.M111.257220.CrossRefPubMedPubMedCentral

40.

Pérez-Sánchez J, Bermejo-Nogales A, Calduch-Giner JA, Kaushik S, Sitjà-Bobadilla A: Molecular characterization and expression analysis of six peroxiredoxin paralogous genes in gilthead sea bream (Sparus aurata): insights from fish exposed to dietary, pathogen and confinement stressors. Fish Shellfish Immunol. 2011, 31 (2): 294-302. 10.1016/j.fsi.2011.05.015.CrossRefPubMed

41.

Qiu L, Ma Z, Jiang S, Wang W, Zhou F, Huang J, Li J, Yang Q: Molecular cloning and mRNA expression of peroxiredoxin gene in black tiger shrimp (Penaeus monodon). Mol Biol Rep. 2010, 37 (6): 2821-2827. 10.1007/s11033-009-9832-8.CrossRefPubMed

42.

Hazane-Puch F, Benaraba R, Valenti K, Osman M, Laporte F, Favier A, Anderson RA, Roussel AM, Hininger-Favier I: Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010, 137 (1): 23-39. 10.1007/s12011-009-8557-9.CrossRefPubMed

43.

Diet A, Abbas K, Bouton C, Guillon B, Tomasello F, Fourquet S, Toledano MB, Drapier JC: Regulation of peroxiredoxins by nitric oxide in immunostimulated macrophages. J Biol Chem. 2007, 282 (50): 36199-36205. 10.1074/jbc.M706420200.CrossRefPubMed

44.

Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P: Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer. 2010, 46 (9): 1661-1667. 10.1016/j.ejca.2010.02.006.CrossRefPubMed

45.

Hayder N, Bouhlel I, Skandrani I, Kadri M, Steiman R, Guiraud P, Mariotte AM, Ghedira K, Dijoux-Franca MG, Chekir-Ghedira L: In vitro antioxidant and antigenotoxic potentials of myricetin-3-o-galactoside and myricetin-3-o-rhamnoside from Myrtus communis: modulation of expression of genes involved in cell defence system using cDNA microarray. Toxicol In Vitro. 2008, 22 (3): 567-581. 10.1016/j.tiv.2007.11.015.CrossRefPubMed

46.

Hansen J, Palmfeldt J, Vang S, Corydon TJ, Gregersen N, Bross P: Quantitative proteomics reveals cellular targets of celastrol. PLoS One. 2011, 6 (10): e26634-10.1371/journal.pone.0026634.CrossRefPubMedPubMedCentral

47.

Yerbury JJ, Stewart EM, Wyatt AR, Wilson MR: Quality control of protein folding in extracellular space. EMBO Rep. 2005, 6 (12): 1131-1136. 10.1038/sj.embor.7400586.CrossRefPubMedPubMedCentral

48.

Palande K, Roovers O, Gits J, Verwijmeren C, Iuchi Y, Fujii J, Neel BG, Karisch R, Tavernier J, Touw IP: Peroxiredoxin-controlled G-CSF signalling at the endoplasmic reticulum-early endosome interface. J Cell Sci. 2011, 124 (Pt 21): 3695-3705.CrossRefPubMedPubMedCentral

49.

Park JJ, Chang HW, Jeong EJ, Roh JL, Choi SH, Jeon SY, Ko GH, Kim SY: Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009, 73 (4): 1196-1202. 10.1016/j.ijrobp.2008.10.070.CrossRefPubMed

50.

Wang HQ, Du ZX, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY: TNF-related apoptosis-inducing ligand suppresses PRDX4 expression. FEBS Lett. 2009, 583 (9): 1511-1515. 10.1016/j.febslet.2009.04.009.CrossRefPubMed

51.

Crowley-Weber CL, Payne CM, Gleason-Guzman M, Watts GS, Futscher B, Waltmire CN, Crowley C, Dvorakova K, Bernstein C, Craven M, Garewal H, Bernstein H: Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis. 2002, 23 (12): 2063-2080. 10.1093/carcin/23.12.2063.CrossRefPubMed

52.

Lee YS, Chang HW, Jeong JE, Lee SW, Kim SY: Proteomic analysis of two head and neck cancer cell lines presenting different radiation sensitivity. Acta Otolaryngol. 2008, 128 (1): 86-92. 10.1080/00016480601110196.CrossRefPubMed

53.

Shen C, Nathan C: Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med. 2002, 8 (2): 95-102.PubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/9/137/prepub

Title: Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration
Author: Janin Schulte
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2011
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-9-137

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Acute kidney injury biomarkers: renal angina and the need for a renal troponin I

MUC4gene polymorphisms associate with endometriosis development and endometriosis-related infertility

Perceptions of general practitioners towards the use of a new system for treating back pain: a qualitative interview study

Buyer beware? Does the information provided with herbal products available over the counter enable safe use?

Even low level of physical activity is associated with reduced mortality among people with metabolic syndrome, a population based study (the HUNT 2 study, Norway)

Q&A: The 'three Ps' of cancer survivorship care